LFB is a biopharmaceutical group that develops, manufactures and markets medicinal products for the treatment of serious and often rare diseases in several major therapeutic fields, namely Hemostasis, Immunology and Intensive Care.
With most of its products indicated for serious and rare diseases, LFB is a major player in this area.
The LFB Group is the leading manufacturer of plasma-derived medicinal products in France and 5th worldwide and is also among the leading European companies for the development of new-generation proteins and treatments based on biotechnologies.
With a sustained investment in research and development, the LFB Group bases its strategy on its international deployment and the design of innovative therapies.
|
|
|
1,001-5,000 employees
View all LFB employees
|
|
Pharmaceuticals
|
|
3 avenue des Tropiques - BP 305 Les Ulis - Zone d'activités de Courtaboeuf, Les Ulis, France 91940, FR
|
|
1994
|
|
Bioproduction, Médicaments Dérivés Du Plasma, Médicaments Issus Du Vivant
|
Benjamin Mery is the CEO of LFB. To contact Benjamin Mery email at [email protected] or [email protected]. Or you may call +33.674761746
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.